EFCAB12

Summary

EFCAB12 (EF-hand calcium binding domain 12, HGNC:28061) is a protein-coding gene on chromosome 3q21.3, encoding EF-hand calcium-binding domain-containing protein 12 (Q6NXP0).

Predicted to enable calcium ion binding activity.

Source: NCBI Gene 90288 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 104 total — 1 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_207307

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28061
Approved symbol	EFCAB12
Name	EF-hand calcium binding domain 12
Location	3q21.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000172771
Ensembl biotype	protein_coding
Entrez	90288

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 retained_intron, 2 protein_coding

ENST00000503498, ENST00000503957, ENST00000505956, ENST00000514900

RefSeq mRNA: 1 — MANE Select: NM_207307 NM_207307

CCDS: CCDS54638

Canonical transcript exons

ENST00000505956 — 9 exons

Exon	Start	End
ENSE00002078715	129401321	129401851
ENSE00002319121	129421367	129421803
ENSE00003567465	129402523	129402579
ENSE00003571521	129411158	129411354
ENSE00003576447	129415245	129415401
ENSE00003597385	129408645	129408858
ENSE00003606408	129418254	129418448
ENSE00003671174	129404250	129404403
ENSE00003844630	129428440	129428636

Expression profiles

Bgee: expression breadth ubiquitous, 160 present calls, max score 97.10.

FANTOM5 (CAGE): breadth broad, TPM avg 1.1949 / max 107.8840, expressed in 315 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
44519	1.1949	315

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	97.10	gold quality
bronchial epithelial cell	CL:0002328	93.57	gold quality
bronchus	UBERON:0002185	92.42	gold quality
mucosa of paranasal sinus	UBERON:0005030	83.82	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	83.55	gold quality
oviduct epithelium	UBERON:0004804	82.51	gold quality
fallopian tube	UBERON:0003889	80.21	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.50	gold quality
adenohypophysis	UBERON:0002196	76.33	gold quality
pituitary gland	UBERON:0000007	76.22	gold quality
nasal cavity epithelium	UBERON:0005384	75.93	gold quality
epithelium of nasopharynx	UBERON:0001951	75.20	silver quality
left testis	UBERON:0004533	74.55	gold quality
right testis	UBERON:0004534	74.55	gold quality
testis	UBERON:0000473	73.53	gold quality
caput epididymis	UBERON:0004358	73.26	gold quality
prostate gland	UBERON:0002367	71.44	gold quality
nucleus accumbens	UBERON:0001882	71.12	gold quality
hypothalamus	UBERON:0001898	69.85	gold quality
right lung	UBERON:0002167	69.04	gold quality
nasal cavity mucosa	UBERON:0001826	68.70	gold quality
trachea	UBERON:0003126	68.16	silver quality
right lobe of liver	UBERON:0001114	67.94	gold quality
cerebellar hemisphere	UBERON:0002245	67.55	gold quality
right lobe of thyroid gland	UBERON:0001119	67.45	gold quality
cerebellar cortex	UBERON:0002129	67.44	gold quality
caudate nucleus	UBERON:0001873	67.06	gold quality
right hemisphere of cerebellum	UBERON:0014890	66.88	gold quality
cerebellum	UBERON:0002037	66.84	gold quality
kidney epithelium	UBERON:0004819	66.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting EFCAB12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-642A-5P	99.51	65.10	1152
HSA-MIR-3668	98.52	68.76	951
HSA-MIR-581	98.39	67.42	835
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-876-5P	97.99	68.49	1345
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-4329	97.68	66.26	1003
HSA-MIR-3167	96.81	67.09	1236
HSA-MIR-2276-5P	96.27	65.85	937

Cross-species orthologs

15 orthologs

Organism	Symbol	Gene ID
mus_musculus	Efcab12	ENSMUSG00000030321
rattus_norvegicus	Efcab12	ENSRNOG00000026176
drosophila_melanogaster	TpnC4	FBGN0033027
drosophila_melanogaster	CG13526	FBGN0034774
drosophila_melanogaster	CG5024	FBGN0039373
drosophila_melanogaster	CG17770	FBGN0039374
drosophila_melanogaster	CG30378	FBGN0050378
caenorhabditis_elegans		WBGENE00000285
caenorhabditis_elegans		WBGENE00000287
caenorhabditis_elegans	pat-10	WBGENE00003934
caenorhabditis_elegans		WBGENE00006583
caenorhabditis_elegans		WBGENE00008453
caenorhabditis_elegans	F35C12.3	WBGENE00009408
caenorhabditis_elegans		WBGENE00015264
caenorhabditis_elegans		WBGENE00019352

Paralogs (20): CABP7 (ENSG00000100314), CABP5 (ENSG00000105507), CALML4 (ENSG00000129007), CALM2 (ENSG00000143933), CETN2 (ENSG00000147400), CETN3 (ENSG00000153140), CABP1 (ENSG00000157782), CALM3 (ENSG00000160014), CABP2 (ENSG00000167791), CALML6 (ENSG00000169885), EFCAB3 (ENSG00000172421), CABP4 (ENSG00000175544), CETN1 (ENSG00000177143), CALML3 (ENSG00000178363), CALML5 (ENSG00000178372), CALN1 (ENSG00000183166), CALM1 (ENSG00000198668), EFCAB2 (ENSG00000203666), EFCAB7 (ENSG00000203965), EFCAB9 (ENSG00000214360)

Protein

Protein identifiers

EF-hand calcium-binding domain-containing protein 12 — Q6NXP0 (reviewed: Q6NXP0)

All UniProt accessions (2): Q6NXP0, D6RFI2

RefSeq proteins (1): NP_997190* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR042847	EFC12	Family

UniProt features (10 total): sequence variant 5, region of interest 2, chain 1, domain 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NXP0-F1	65.48	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 212

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 34 (showing top): chr3q21, DODD_NASOPHARYNGEAL_CARCINOMA_DN, MIKKELSEN_ES_ICP_WITH_H3K4ME3, IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP, FOXN3_TARGET_GENES, ZNF10_TARGET_GENES, ZNF92_TARGET_GENES, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2, MIR488_3P, GSE8685_IL2_ACT_IL2_STARVED_VS_IL21_ACT_IL2_STARVED_CD4_TCELL_UP, GSE14026_TH1_VS_TH17_UP, BLANCO_MELO_HUMAN_PARAINFLUENZA_VIRUS_3_INFECTION_A594_CELLS_DN, BLANCO_MELO_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_A594_CELLS_DN, DESCARTES_MAIN_FETAL_CILIATED_EPITHELIAL_CELLS, DESCARTES_FETAL_CEREBRUM_ASTROCYTES

GO Biological Process (0):

GO Molecular Function (3): calcium ion binding (GO:0005509), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metal ion binding	1
binding	1
cation binding	1

Protein interactions and networks

STRING

326 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EFCAB12	SLC68A1	Q14CX5	477
EFCAB12	KHDC4	Q7Z7F0	462
EFCAB12	MPV17L2	Q567V2	412
EFCAB12	MRPS33	Q9Y291	409
EFCAB12	UQCC1	Q9NVA1	399
EFCAB12	CFAP61	Q8NHU2	392
EFCAB12	WSCD2	Q2TBF2	386
EFCAB12	PTPDC1	A2A3K4	378
EFCAB12	DDX52	Q9Y2R4	375
EFCAB12	WDPCP	O95876	372
EFCAB12	CFAP65	Q6ZU64	370
EFCAB12	CCDC92	Q53HC0	366
EFCAB12	ITPK1	Q13572	359
EFCAB12	LRRC47	Q8N1G4	359
EFCAB12	NUCKS1	Q9H1E3	336

IntAct

5 interactions, top by confidence:

A	B	Type	Score
FHL3	EFCAB12	psi-mi:“MI:0915”(physical association)	0.560
EFCAB12	FHL3	psi-mi:“MI:0915”(physical association)	0.560
EFCAB12	H1-2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (8): EFCAB12 (Two-hybrid), EFCAB12 (Synthetic Lethality), EFCAB12 (Biochemical Activity), EFCAB12 (Proximity Label-MS), EFCAB12 (Cross-Linking-MS (XL-MS)), EFCAB12 (Cross-Linking-MS (XL-MS)), EFCAB12 (Cross-Linking-MS (XL-MS)), EFCAB12 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A1B0GTD5, A0A1B0GUX0, A0A3Q1MT14, A4D263, A6NL82, A6QQL5, A8QW39, B0UXH9, B5X5D0, B9EJX3, E1B9R1, F1MMV1, Q148A4, Q1JPL0, Q2T9T0, Q32KQ1, Q32L72, Q32L77, Q32P67, Q3V0J4, Q5BN46, Q5NC57, Q5NC83, Q5SPV6, Q5SS90, Q5SVJ3, Q5VTT2, Q5VZQ5, Q66HC0, Q66HR9, Q6AYM0, Q6NXP0, Q6P3G4, Q6ZVS7, Q80X60, Q8CDT5, Q8CDU5, Q8N5S3, Q8N7U6, Q8N865

Diamond homologs: Q6NXP0, Q95LL8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	82
Likely benign	10
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
4075854	GRCh37/hg19 3q21.3-22.1(chr3:129108935-129214595)x1	Pathogenic

SpliceAI

1947 predictions. Top by Δscore:

Variant	Effect	Δscore
3:129401848:CTTC:C	acceptor_gain	1.0000
3:129401849:TTCC:T	acceptor_loss	1.0000
3:129401852:C:CC	acceptor_gain	1.0000
3:129401852:CTGGA:C	acceptor_loss	1.0000
3:129402493:T:TA	donor_gain	1.0000
3:129404248:G:C	donor_gain	1.0000
3:129411153:GGTAC:G	donor_loss	1.0000
3:129411154:GTA:G	donor_loss	1.0000
3:129411155:TA:T	donor_loss	1.0000
3:129411156:A:AT	donor_loss	1.0000
3:129411157:C:A	donor_loss	1.0000
3:129411198:T:TA	donor_gain	1.0000
3:129411362:C:CT	acceptor_gain	1.0000
3:129411363:A:T	acceptor_gain	1.0000
3:129415243:A:AC	donor_gain	1.0000
3:129415243:ACGCT:A	donor_gain	1.0000
3:129415244:C:CC	donor_gain	1.0000
3:129415244:CG:C	donor_gain	1.0000
3:129415244:CGCT:C	donor_gain	1.0000
3:129415244:CGCTC:C	donor_gain	1.0000
3:129415248:C:CA	donor_gain	1.0000
3:129415400:ACCTG:A	acceptor_loss	1.0000
3:129415401:CCT:C	acceptor_loss	1.0000
3:129415403:T:G	acceptor_loss	1.0000
3:129418252:A:AC	donor_gain	1.0000
3:129418253:C:CC	donor_gain	1.0000
3:129418253:CTG:C	donor_gain	1.0000
3:129421327:AAAC:A	donor_gain	1.0000
3:129421365:AC:A	donor_gain	1.0000
3:129421366:CC:C	donor_gain	1.0000

AlphaMissense

3783 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:129418273:A:G	F221S	0.976
3:129401722:G:C	F530L	0.975
3:129401722:G:T	F530L	0.975
3:129401724:A:G	F530L	0.975
3:129401797:G:C	F505L	0.967
3:129401797:G:T	F505L	0.967
3:129401799:A:G	F505L	0.967
3:129415352:A:G	L244P	0.964
3:129418272:G:C	F221L	0.964
3:129418272:G:T	F221L	0.964
3:129418274:A:G	F221L	0.964
3:129401796:A:G	W506R	0.957
3:129401796:A:T	W506R	0.957
3:129401723:A:G	F530S	0.946
3:129421480:A:G	W125R	0.941
3:129421480:A:T	W125R	0.941
3:129401794:C:A	W506C	0.935
3:129401794:C:G	W506C	0.935
3:129415394:A:T	V230D	0.931
3:129418354:A:G	L194P	0.929
3:129402537:A:C	F482L	0.928
3:129402537:A:T	F482L	0.928
3:129402539:A:G	F482L	0.928
3:129401771:A:G	L514P	0.925
3:129415364:A:T	I240K	0.922
3:129421727:G:C	F42L	0.922
3:129421727:G:T	F42L	0.922
3:129421729:A:G	F42L	0.922
3:129415325:A:C	I253S	0.918
3:129415290:A:G	W265R	0.915

dbSNP variants (sampled 300 via entrez): RS1000015940 (3:129421050 T>C), RS1000098522 (3:129428754 A>G,T), RS1000150307 (3:129417347 A>C), RS1000237120 (3:129422337 T>C), RS1000296692 (3:129416025 C>A,T), RS1000298775 (3:129410033 C>T), RS1000522124 (3:129411632 T>A), RS1000571706 (3:129404678 C>G), RS1000739340 (3:129407146 G>C,T), RS1001039614 (3:129411331 C>A,G,T), RS1001125354 (3:129404874 C>G,T), RS1001366304 (3:129412399 C>T), RS1001418693 (3:129412695 C>G), RS1001462267 (3:129406527 G>A,T), RS1001553716 (3:129430213 A>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST002875_11	Diisocyanate-induced asthma	2.000000e-06
GCST005551_4	Systemic sclerosis (anti-topoisomerase-positive)	3.000000e-06
GCST005956_82	Waist-to-hip ratio adjusted for BMI	2.000000e-07
GCST005958_5	Waist-to-hip ratio adjusted for BMI (age >50)	4.000000e-10
GCST005962_16	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	2.000000e-11
GCST007483_52	Waist-to-hip ratio adjusted for BMI (additive genetic model)	8.000000e-17
GCST007487_16	Waist-to-hip ratio adjusted for BMI (additive genetic model)	2.000000e-18
GCST007500_19	Waist-to-hip ratio adjusted for BMI (additive genetic model)	8.000000e-18
GCST007502_15	Waist-to-hip ratio adjusted for BMI (additive genetic model)	5.000000e-19
GCST90020024_1254	A body shape index	4.000000e-13
GCST90020025_594	Waist-to-hip ratio adjusted for BMI	5.000000e-22
GCST90020027_371	Waist-hip index	2.000000e-21
GCST90020028_1841	Hip circumference adjusted for BMI	3.000000e-09
GCST90020029_1349	Waist circumference adjusted for body mass index	3.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0006995	response to diisocyanate
EFO:0008537	anti-topoisomerase-I-antibody-positive systemic scleroderma
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	decreases expression, decreases methylation, increases methylation	3
Benzo(a)pyrene	affects methylation, decreases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
triphenyl phosphate	affects expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
mancozeb	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
clothianidin	decreases expression	1
enzalutamide	decreases expression	1
(+)-JQ1 compound	increases expression	1
Air Pollutants	increases expression, increases abundance	1
Lipopolysaccharides	affects response to substance, increases expression	1
Smoke	increases abundance, increases expression	1
Dihydrotestosterone	increases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms